Table 3. The risk profiles of c-Met inhibitor in advanced or metastatic NSCLC treatment.
| Adverse events | All Grades | Grade ≥ 3 | ||||
|---|---|---|---|---|---|---|
| No. of trials | RR [95% CI] | P value | No. of trials | RR [95% CI] | P value | |
| Abnormal liver function | 4 | 1.68 [0.82, 3.46] | 0.16 | 3 | 2.67 [0.54, 13.21] | 0.23 |
| Anemia | 5 | 1.16 [0.47, 2.85] | 0.75 | 6 | 1.03 [0.26, 4.11] | 0.96 |
| Constipation | 4 | 1.42 [1.00, 2.03] | 0.05 | 2 | 7.88 [0.99, 62.79] | 0.05 |
| Cough | 3 | 1.17 [0.96, 1.44] | 0.13 | 1 | 1.49 [0.42, 5.25] | 0.53 |
| Dermatitis acneiform | 3 | 1.00 [0.68, 1.49] | 0.98 | 2 | 1.39 [0.44, 4.37] | 0.57 |
| Diahhrea | 6 | 1.36 [0.82, 2.26] | 0.23 | 5 | 0.90 [0.54, 1.52] | 0.70 |
| Dyspnea | 5 | 0.96 [0.82, 1.12] | 0.60 | 5 | 0.94 [0.60, 1.47] | 0.77 |
| Edema | 7 | 3.23 [2.24, 4.64] | <0.0001 | 6 | 3.81 [1.23, 11.75] | 0.02 |
| Fatigue | 5 | 0.91 [0.74, 1.12] | 0.37 | 5 | 1.10 [0.78, 1.56] | 0.57 |
| ILD | 3 | 1.37 [0.55, 3.45] | 0.5 | 2 | 4.47 [1.15, 17.45] | 0.03 |
| Leukopenia | 3 | 3.64 [0.19, 69.27] | 0.39 | 2 | 3.70 [0.02, 568.74] | 0.61 |
| Nausea | 5 | 1.07 [0.88, 1.30] | 0.49 | 5 | 0.50 [0.22, 1.11] | 0.09 |
| Neutropenia | 4 | 3.70 [0.73, 18.66] | 0.11 | 5 | 2.55 [0.78, 8.40] | 0.12 |
| Pyrexia | 3 | 1.15 [0.50, 2.64] | 0.74 | 3 | 0.55 [0.09, 3.37] | 0.52 |
| Rash | 6 | 0.96 [0.84, 1.10] | 0.53 | 3 | 0.95 [0.46, 1.97] | 0.90 |
| Respiratory infection | 3 | 2.24 [1.63, 3.07] | <0.0001 | 3 | 1.24 [0.34, 4.60] | 0.74 |
| Vomiting | 5 | 1.25 [0.76, 2.05] | 0.39 | 4 | 1.00 [0.44, 2.24] | 0.99 |
| VTE | 4 | 1.80 [0.87, 3.70] | 0.11 | 4 | 1.78 [0.88, 3.59] | 0.11 |
Abbreviations: ILD - Interstitial lung disease; VTE - Venous thromboembolism.